(Q46164408)

20 December 2017

title

A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia (English)

1 reference

20 December 2017

0 references

0 references

1 reference

1

Jeffrey A Lieberman

1 reference

20 December 2017

author name string

Kelly Papadakis

2

1 reference

20 December 2017

John Csernansky

3

1 reference

20 December 2017

Robert Litman

4

1 reference

20 December 2017

Jan Volavka

5

1 reference

20 December 2017

Xinwei Daniel Jia

6

1 reference

20 December 2017

Allyson Gage

7

1 reference

20 December 2017

MEM-MD-29 Study Group

8

1 reference

20 December 2017

language of work or name

English

0 references

publication date

12 November 2008

1 reference

20 December 2017

published in

Neuropsychopharmacology

1 reference

20 December 2017

volume

34

1 reference

20 December 2017

issue

5

1 reference

20 December 2017

page(s)

1322-1329

1 reference

20 December 2017

https://scigraph.springernature.com/pub.10.1038/npp.2008.200

exact match

0 references

cites work

Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Imaging the glutamatergic system in vivo--relevance to schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Ionotropic glutamate receptors as therapeutic targets in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

A two-process theory of schizophrenia: evidence from studies in post-mortem brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

An open-label, flexible-dose study of memantine in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Recent advances in the phencyclidine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Neurocognitive impairment across the lifespan in schizophrenia: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Glutamatergic mechanisms in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Treatment-refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Network interactions in schizophrenia - therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Cognition as an outcome measure in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Long-term combination antipsychotic treatment in VA patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

[Polypharmacy in the treatment of schizophrenia]

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2008.200

7 January 2021

Identifiers

DOI

10.1038/NPP.2008.200

1 reference

20 December 2017

Dimensions Publication ID

1028995555

0 references

1 reference

20 December 2017